Alcohol Use clinical trials

Explore recruiting alcohol use clinical trials.

Recruiting alcohol use studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Alcohol Use trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

J2S-MC-GZMP: A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Alcohol Use Disorder (RENEW-ALC-2)

Germany, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

Psilocybin in alcohol use disorder with comorbid depression - Randomized double-blind controlled pilot study.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Study to Evaluate Impact of Sunobinop (V117957) on Alcohol Consumption (Part A) and Alcohol Craving (Part B) in Subjects Diagnosed with Moderate to Severe Alcohol Use Disorder and Seeking Treatment

Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 1, open-label, cross-over study in healthy volunteers to assess the pharmacokinetic profile of Prazosin and Cyproheptadine following single dose oral administration of KT110 tablet and following administration of Alpress and Periactine marketed tablets

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Does the Glucagon-like Peptide 1 (GLP-1) receptor agonist semaglutide reduce alcohol intake in patients with Alcohol Use Disorder and comorbid obesity?

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Can a one-off administration of psilocybin reduce alcohol intake in patients with alcohol use disorder? A randomized, double-blinded, placebo-controlled clinical trial.

Denmark

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Alcohol Use trials by city

Alcohol Use in Toronto Alcohol Use in Vancouver Alcohol Use in Montreal Alcohol Use in Calgary Alcohol Use in Edmonton Alcohol Use in Ottawa Alcohol Use in Winnipeg Alcohol Use in Quebec City Alcohol Use in Hamilton Alcohol Use in Kitchener Alcohol Use in London Alcohol Use in Halifax Alcohol Use in New York Alcohol Use in Los Angeles Alcohol Use in Chicago Alcohol Use in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease